Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer

Summary

This trial studies the side effects of pembrolizumab with or without chemotherapy in treating patients with stage IV non-small cell lung cancer that has come back (recurrent) and has spread to other places in the body (advanced). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as pemetrexed and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with or without chemotherapy may shrink the tumor in older patients with non-small cell lung cancer.

Timeline

Start

2020-11-16

Primary completion

2023-10-31

Completion

2027-05-31

Publications

• Wong ML, Lee MK, Kour O, Satele D, Presley CJ, Le-Rademacher J, Ojelabi M, Chow S, Stinchcombe TE, Homan S, Finnes HD, Waqar S, Jatoi A. Pembrolizumab with or without chemotherapy among older adults with advanced lung adenocarcinoma: a national, nonrandomized open-label phase II trial (Alliance A171901). J Natl Cancer Inst. 2026 May 20:djag157. doi: 10.1093/jnci/djag157. Online ahead of print.

Drugs

Indications